Jounce Therapeutics — AACR Annual Meeting 2017
27 slides from Jounce Therapeutics's conference presentation, Apr 3, 2017
Slide 1: Preclinical Assessment of JTX-2011, An Agonist Antibody Targeting ICOS
Preclinical Assessment of JTX-2011, An Agonist Antibody Targeting ICOS, Supports Evaluation In ICONIC Clinical Trial Jennifer Michaelson, Ph.D. AACR Annual Meeting April 2, 2017 Major Symposium “Emerging Targets in Immunotherapy” Exhibit 99.1
Slide 2: Comprehensive Interrogation of the TME to Develop a Sustainable Innovative Pipeline
Sustainable immunotherapy pipeline Comprehensive interrogation of the TME Identifying optimal immune cell targets and developing new immunotherapies Patient enrichment strategies using predictive biomarkers Translational Science Platform Comprehensive Interrogation of the TME to Develop a Sustainabl
Slide 3: Many Potential Targets: Why Choose ICOS?
Many Potential Targets: Why Choose ICOS? • Data from Founders’ labs demonstrated clinical correlate and outcome data that supported activation of ICOS • Subsequent laboratory evidence in animal tumor reduction studies Adapted from Mellman et al. Nature 480, 480-489 (2011) ICOS ICOS Jounce Approach 3
Slide 4: Many Potential Targets: Why Choose ICOS?
Many Potential Targets: Why Choose ICOS? Human clinical and mouse preclinical data support activating ICOS receptor for anti-tumor benefit Chen et al, PNAS (2009); Carthon et al, Clin Can Res (2010); Ng Tang et al, Canc Immunol Res (2013) 4 | Jounce Therapeutics © 2017 Impaired Tumor Rejection In IC
Slide 5: JTX-2011: ICOS Agonist Antibody
JTX-2011: ICOS Agonist Antibody • Specificity for ICOS • Species cross-reactive • Agonist activity • Humanized rodent antibody • hIgG1 Fc backbone 5 | Jounce Therapeutics © 2017 JTX-2011: Key Features
Slide 6: JTX-2011 Dual Mechanism Shifts Balance of T Cells Towards Anti-Tumor Activity
JTX-2011 Dual Mechanism Shifts Balance of T Cells Towards Anti-Tumor Activity APC “Primed” T effector cell ICOS↑ TCR 1st signal ICOS JTX-2011 ↑ IFN-γ↑ ↑ IFN-γ↑ Activation of T eff T regulatory cell NK cell X Reduction of T regs 6 | Jounce Therapeutics © 2017 JTX-2011 is designed to • Stimulate T eff
Slide 7: JTX-2011 Stimulates Primed Human T Cells
JTX-2011 Stimulates Primed Human T Cells No Indiscriminate Activation of T cells Activation of primed CD4+ T effector cells No activation of unprimed CD4+ T effector cells % D iv ided Ce lls No Antibody Anti-CD28 Super agonist anti-CD28 JTX-2011 Control Antibody Un st im ul at ed + co nt ro l a nt i
Slide 8: JTX-2011 Induces Signaling Through AKT Pathway
JTX-2011 Induces Signaling Through AKT Pathway • ICOS antibody re-capitulates signaling activity of ICOS ligand – Induces pAKT signal in CD4+ T cells when cross-linked ICOS JTX-2011 p85 p 1 1 0 PI(3)K Control Antibody Control Antibody + Cross-Linker JTX-2011 JTX-2011 + Cross-Linker AKT 8 | Jounce Th
Slide 9: JTX-2011 Dual Mechanism Shifts Balance of T Cells Towards Anti-Tumor Activity
JTX-2011 Dual Mechanism Shifts Balance of T Cells Towards Anti-Tumor Activity 9 | Jounce Therapeutics © 2017 “Primed” T effector cell ICOS↑ APC TCR 1st signal ICOS JTX-2011 ↑ IFN-γ↑ ↑ IFN-γ↑ Activation of T eff T regulatory cell NK cell X Reduction of T regs JTX-2011 is designed to • Stimulate T eff
Slide 10: Selective Reduction in Tumor but Not Peripheral T Regulatory Cells
Selective Reduction in Tumor but Not Peripheral T Regulatory Cells Mouse JTX-2011 selectively reduces tumor T regulatory cells in vivo Day: 0 7 10 12 Treatment (0.2mg/kg) TIL analysis Implant Tumor m Ig G 2 a 3 7 A 1 0 -m G 2 a J T X -1 0 1 1 - m G 2 a 0 2 0 4 0 6 0 8 0 1 0 0 % S u b s e t in C D 3
Slide 11: ICOS Expression is Highest on Mouse and Human Intratumoral Tregs
ICOS Expression is Highest on Mouse and Human Intratumoral Tregs Multiplexed IF Flow cytometry 11 | Jounce Therapeutics © 2017
Slide 12: Selective Reduction of Tregs vs Teffs in vitro
Selective Reduction of Tregs vs Teffs in vitro • ICOS antibody selectively depletes Tregs from IL-2 activated PMBC • Under these in vitro activation conditions, Tregs and Teffs express similar levels of ICOS 12 | Jounce Therapeutics © 2017 10 -5 10 -4 10 -3 10 -2 10 -1 100 101 102 103 -70 -60 -50 -4
Slide 13: Single Agent Development of JTX-2011 Supported by Long-Lasting Response in Preclinical Tumor Models
Single Agent Development of JTX-2011 Supported by Long-Lasting Response in Preclinical Tumor Models 0 10 20 30 40 0 200 400 600 800 1000 1200 1400 0 10 20 30 40 0 200 400 600 800 1000 1200 1400 Days post-inoculation of tumor cells T umor vo lume (m m 3 ) Control ICOS Antibody Sa1/N Tumors 1/10 7/10
Slide 14: Fc Effector Function is Required for Optimal Anti-Tumor Activity
Fc Effector Function is Required for Optimal Anti-Tumor Activity Loss of Activity with Fc Deficient Version of Antibody T u m o r v o lu m e ( m m 3 ) 0 1 0 2 0 3 0 4 0 0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 0 1 0 2 3 0 4 0 0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 0 1 0 2 3 0 4 0 0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 Con
Slide 15: Combination Development of JTX-2011 with Anti-PD-1 Supported by Enhanced Anti-tumor Activity
0 10 20 30 40 0 500 1000 1500 2000 Days Post-Inoculation 0 10 20 30 40 0 500 1000 1500 2000 Days Post-Inoculation 0 10 20 30 40 0 500 1000 1500 2000 Days Post-Inoculation 0 10 20 30 40 0 500 1000 1500 2000 Days P st-Inoculation Combination Development of JTX-2011 with Anti-PD-1 Supported by Enhanced
Slide 16: Preclinical Safety Features of JTX-2011
Preclinical Safety Features of JTX-2011 • No cytokine storm in GLP toxicology studies • No cytokine induction by JTX-2011 alone or in combination with Opdivo® in human whole blood assays • NOAEL = 50 mg/kg; highest dose tested in cynomolgus monkey IND-enabling GLP toxicology study JTX-2011-induced T
Slide 17: Pharmacodynamic Biomarker: Target Engagement in Mouse
Pharmacodynamic Biomarker: Target Engagement in Mouse Efficacy in Syngeneic Mouse Tumor Model Correlates with Duration of ICOS Target Engagement 50 100 150 200 -50 0 50 100 150 200 Time post-dose (Hours) % R ec ep to r A va ilb al e 2.5mg/kg 0.25mg/kg 0.05mg/kg 0.05mg/kg 0.25mg/kg 2.5mg/kg Tumor Fre
Slide 18: Preclinical Pharmacokinetics and Pharmacodynamics
Preclinical Pharmacokinetics and Pharmacodynamics PK and PD in Cynomolgus Monkey Preclinical Studies • Pharmacokinetics: – T1/2 = 5-12 days in ADA-negative monkeys • Pharmacodynamic readouts – Target engagement: ICOS is fully engaged for the duration of the dosing interval at all doses – JTXP induct
Slide 19: Preclinical QSP Modeling of JTX-2011
Preclinical QSP Modeling of JTX-2011 Predictions for PK and Target Engagement in First-in-Human Study 19 | Jounce Therapeutics © 2017 starting dose highest dose starting dose highest dose
Slide 20: Patient Selection Strategy Supported by Mouse Models
Patient Selection Strategy Supported by Mouse Models Better Single-Agent Efficacy in Tumors Expressing Higher Levels of Intra-Tumoral ICOS ++++ indicates 61-100% tumor regression +++ indicates 41-60% tumor regression ++ indicates 21-40% tumor regression + indicates 10-20% tumor regression - indicate
Slide 21: Indication Selection & Patient Enrichment
Indication Selection & Patient Enrichment ICOS Immunohistochemistry (IHC) Re na l Br ea st Bl ad de r Ov ar ian Pr os tat e St om ac h Co lon Me lan om a TN BC Lu ng HN SC C 0 50 100 % T um or s 3+ 2+ 1+ None ICOS protein levels vary across indications1 ICOS protein levels within high ICOS indicatio
Slide 22: Integrated Approach to Understanding ICOS in the Context of Immune Oncology Landscape
Integrated Approach to Understanding ICOS in the Context of Immune Oncology Landscape 22 | Jounce Therapeutics © 2017 1000s of human tumors interrogated Collaborations with premier Institutions Integrated TCGA and Internal Data Analysis Patient enrichment for our clinical trials
Slide 23: Translational Science Platform Informs Biomarker Strategy
Translational Science Platform Informs Biomarker Strategy Example from NSCLC ICOS expression levels across subtypes of NSCLC tumors ICOS levels are not associated with smoker status 23 | Jounce Therapeutics © 2017 A subset of PD-L1 low tumors have high levels of ICOS expression
Slide 24: Biomarker-Driven Enrichment Strategy
Biomarker-Driven Enrichment Strategy Biomarker-Driven Strategy for Patient Enrichment Potential for Establishing Complementary and/or Companion Diagnostics Study Enrollment Patient Enrollment All Tumors Indication Selection Patient Enrichment 24 | Jounce Therapeutics © 2017
Slide 25: ICONIC: Adaptive, Biomarker-Driven Clinical Study
ICONIC: Adaptive, Biomarker-Driven Clinical Study Phase 1/2 Preliminary Efficacy Proof-of-Concept * Additional indications, including niche indications, identified through Jounce Translational Science Platform Any solid tumor type HNSCC NSCLC New indications based on emerging science* C NSCLC HNSCC
Slide 26: JTX-2011: Agonist Monoclonal Antibody that Targets ICOS
JTX-2011: Agonist Monoclonal Antibody that Targets ICOS • Member of family of immune modulators that includes PD-1 and CTLA-4 • Potential importance of ICOS supported by key clinical observations • Pharmacological activity is focused in the tumor • Significant anti-tumor activity seen in preclinical
Slide 27: Thank You
Jounce Therapeutics Debbie Law Elizabeth Trehu Christopher Harvey Heather Hirsch Jason Reeves Tyler Simpson Lindsey Shallberg Matt Wallace Sriram Sathy Robert Mabry Amit Deshpande Steve Sazinsky Kutlu Elpek Ellen Duong Jenny Shu Tong Zi Jim Allison Pam Sharma Tanguy Seiwart David Rimm Applied Biomat